Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

Background and purpose Although erenumab has demonstrated significant reduction in migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is known about long‐term therapy. Methods This study was an open‐label, 5‐year treatment phase following a 12‐week, double‐blin...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of neurology Vol. 28; no. 5; pp. 1716 - 1725
Main Authors:	Ashina, Messoud, Goadsby, Peter J., Reuter, Uwe, Silberstein, Stephen, Dodick, David W., Xue, Fei, Zhang, Feng, Paiva da Silva Lima, Gabriel, Cheng, Sunfa, Mikol, Daniel D.
Format:	Journal Article
Language:	English
Published:	England John Wiley & Sons, Inc 01.05.2021 John Wiley and Sons Inc
Subjects:	Adverse events CGRP receptor efficacy Exposure Headache headache frequency Influenza Migraine Monoclonal antibodies monoclonal antibody Original Patients Placebos Quality of life Reduction Respiratory tract Respiratory tract diseases Rhinopharyngitis Safety Standard error CGRP receptor headache headache frequency monoclonal antibody efficacy
ISSN:	1351-5101, 1468-1331, 1468-1331
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!